US: Justice Department may seek damages from generic drugmakers for price-fixing
According to Bloomberg, some generic drug firms are under pressure in response to a speech delivered by US Department of Justice (DOJ) antitrust division chief Makan Delrahim at George Mason University’s law school. During the speech he said the DOJ may sue generic drug companies to recover damages over alleged pricey-fixing, adding that if taxpayers were overcharged due to collusion to raise prices, then seeking remedies may be appropriate.
If taxpayers were overcharged because drugmakers conspired to raise the price of drugs, the Justice Department will consider suing to seek damages, Makan Delrahim, the division’s chief, said in remarks Friday 19, at George Mason University’s law school in Virginia.
“To the extent that taxpayers have had to pay that bill, I think the taxpayers should recover,” he said. “We will get involved on the civil side and recover damages for the US government.”
Mylan, Teva’s, and Endo are among more than a dozen companies targeted by the Justice Department and state attorneys general in a multi-year investigation into generic drug pricey-fixing. So far, the probe has led to guilty pleas from two former executives of Heritage Pharmaceuticals, a subsidiary of Emcure.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
EU Conducts First-Ever Raids on a Company Under Foreign Subsidies Regulation
Apr 23, 2024 by
CPI
FTC Moves to Ban Non-Compete Agreements, Aiming to Boost Labor Mobility
Apr 23, 2024 by
CPI
Federal Judge Nods at $418M Deal in Real Estate Antitrust Suit
Apr 23, 2024 by
CPI
Mexican Watchdog Probes Amazon and Mercado Libre Over Loyalty Bundles
Apr 23, 2024 by
CPI
Competition Commission of India to Probe AI Landscape for Competition
Apr 23, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI